EGFR and non-small cell lung carcinoma: The TARGET trial is an ongoing phase II trial evaluating the efficacy and safety of adjuvant osimertinib taken for 5 years after surgical resection in patients with stage II-IIIB NSCLC with sensitizing-EGFR mutations (68).